The Effects of ECMO on the Pharmacokinetics of Hydromorphone

Recruiting now · Phase 2

Conditions studied: Extracorporeal Membrane Oxygenation

In brief

The purpose of this study was to establish a population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO, and to recommend a dosing regimen when the target effective concentration was reached.

Key facts

Study ID

NCT05565495

Run by

Xiaobo Yang, MD

People needed

26

Starts

2022-01-01

Expected to finish

2024-09-01

Last updated by the study team

2024-08-06

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Between the ages of 18 and 80;
• Using hydromorphone for pain relief;
• Using ECMO for more than 96h

You may not qualify if…

• Allergic to hydromorphone;
• Use of CRRT during ECMO;
• Liver function Child-Pugh B, C grade;
• Pregnancy;
• Intestinal obstruction;
• Refused to sign the informed consent.

Where it is running

• Wuhan Union Hospital — Wuhan, Hubei, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.